More information
Description
The project aims to develop early diagnostic biomarkers of Alzheimer disease (AD) by validating a series of new biomarkers in serum and cerebrospinal fluid (CSF) in participants from the Czech Brain Aging Study (CBAS).This Czech–Norwegian joint project will involve researchers from CBAS - Czech team with a unique clinical cohort and a top Norwegian research team specialized in mitophagy research. We aim to:
1.)Determine changes of designated mitophagy proteins in serum and CSF of AD individuals compared to non-AD and cognitively normal controls;
2.)Determine the relation to demographics, cognitive status and standard AD biomarkers;
3.)Verify the findings from CBAS on induced pluripotent stem cells and animal models;
4.)Validate specific mitophagy proteins as early diagnostic marker of AD.
Summary of project results
The project aimed to address the need for early diagnostic biomarkers of Alzheimer’s disease (AD). It sought to explore the role of mitophagy (the elimination of damaged mitochondria) in AD. The project also intended to validate specific mitophagy proteins as early diagnostic markers of AD. Alzheimer´s disease, is the most common demenita disease affecting around 55 million people worldwide, thus the research on better diagnosis and treatment is crucial health priority.
The project validated a series of new biomarkers in serum and cerebrospinal fluid (CSF) in participants from the Czech Brain Aging Study (CBAS). It involved researchers from CBAS and a Norwegian research team specialized in mitophagy research. The project identified candidate proteins of mitophagy that are changed in various cognitive stages of AD. It also identified changes in mitophagy marker levels in a clinical population.
The project achieved a utility sample of a System for Tracing Biological Material Samples in Healthcare Facilities and Laboratories. The project also resulted in many publications a was widely disseminated in the medicine community. The reuslts can be used in clinical practice, further research or drug-developmnet industry. The research also benefits the broader scientific and medical communities by advancing knowledge and potential treatment strategies for neurodegenerative diseases.
Summary of bilateral results
The bilateral collaboration leveraged complementary expertise, combining Czech clinical knowledge in Alzheimer’s disease with Oslo’s laboratory expertise in mitophagy, resulting in joint projects, student exchanges, common publications, and shared conference contributions. The partnership continues with follow-up work on sample exchanges, a detailed plan for future research presented at UiO, and a signed memorandum supporting ongoing joint grant applications and collaborative efforts.